secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001193125-23-195289
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea sells global rights to pegzilarginase to Immedica for $15M upfront + up to $100M milestones
--------------------------------------------------------------------------------

- Sold pegzilarginase (for Arginase 1 Deficiency) to Immedica for $15M upfront and up to $100M in milestone payments.
- Milestones contingent on European reimbursement decisions and FDA approval of pegzilarginase.
- Prior license agreement between Aeglea and Immedica terminated in connection with the sale.
- Proceeds net of expenses to be distributed to CVR holders from Spyre merger; first payments expected around Nov 14, 2023.
- Marketing Authorisation Application for pegzilarginase under review by the European Medicines Agency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/0001193125-23-195289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/d473407d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-195289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer